...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochimica et biophysica acta. Molecular basis of disease: BBA >Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma
【24h】

Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma

机译：外部线粒体膜复合亚基20（Tomm20）的译式酶促促进癌症侵袭性和脑膜瘤中的治疗性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chondrosarcoma is the second most common primary bone malignancy, representing one fourth of all primary bone sarcomas. It is typically resistant to radiation and chemotherapy treatments. However, the molecular mechanisms that contribute to cancer aggressiveness in chondrosarcomas remain poorly characterized. Here, we studied the role of mitochondrial transporters in chondrosarcoma aggressiveness including chemotherapy resistance. Histological grade along with stage are the most important prognostic biomarkers in chondrosarcoma. We found that high-grade human chondrosarcoma tumors have higher expression of the mitochondrial protein, translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20), compared to low-grade tumors. TOMM20 overexpression in human chondrosarcoma cells induces chondrosarcoma tumor growth in vivo. TOMM20 drives proliferation, resistance to apoptosis and chemotherapy resistance. Also, TOMM20 induces markers of epithelial to mesenchymal transition (EMT) and metabolic reprogramming in these mesenchymal tumors. In conclusion, TOMM20 drives chondrosarcoma aggressiveness and resistance to chemotherapy.
机译：Chondrosarcoma是第二个最常见的原发性骨骼恶性肿瘤，代表所有原发性骨骼肉瘤中的四分之一。它通常耐辐射和化疗治疗。然而，有助于患有软骨菌瘤的癌症侵袭性的分子机制仍然是较差的。在这里，我们研究了线粒体转运蛋白在软骨肉瘤侵袭性中的作用，包括化学疗法。组织学等级以及阶段是软骨肉瘤中最重要的预后生物标志物。我们发现，与低级肿瘤相比，高级人类软骨瘤肿瘤具有更高的线粒体蛋白质，外部线粒体膜复合亚基20（Tomm20）的译团。 Tomm20在人类软骨肉瘤细胞中的过表达诱导体内软骨菌瘤肿瘤生长。 Tomm20驱动增殖，抗凋亡和化疗抗性。此外，Tomm20诱导上皮的标志物与间充质转换（EMT）和这些间充质肿瘤中的代谢重编程。总之，Tomm20推动了软骨肉瘤的侵袭性和抵抗化疗。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号